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  Introduction
    Patient-reported outcome (PRO) measures are used to 
evaluate the impact of disease and treatment in many 
therapeutic areas. Among the advantages of patient 
report is the potential to capture aspects of the disease 
and treatment experience uniquely accessible to patients 
and, relatedly, to improve the measurement of thera-
peutic intervention eﬀ  ects [1]. Th   e clinician’s specialized 
framework of knowledge makes the clinician the most 
accurate reporter for some aspects of the disease 
experience. For which is the patient the more accurate 
reporter?
Th  e most recent recommendations for core clinical 
criteria for the diagnosis of mild cognitive impairment 
(MCI) due to Alzheimer’s disease (AD) [2] note that 
despite ‘preservation of independence in functional 
abilities’ some impairment in complex functional tasks 
may be evident, such as higher error rate, taking longer, 
and/or being less eﬃ   cient. Th   e companion statement on 
research criteria for preclinical stages of AD [3] raises the 
possibility that biomarkers in combination with ‘subjec-
tive assessment of subtle change will prove to be useful.’ 
Subtle but potentially important features of the disease 
experience may be inaccessible to those other than the 
patient, raising the interesting possibility that the patient 
may have the most comprehensive and accurate know-
ledge of performance [4].
Although impairment in social or occupational 
functioning is part of AD diagnostic criteria [5], the place 
of functioning in diagnostic deﬁ  nitions of MCI is still 
evolving [2,6-8]. Initial deﬁ  nitions of MCI were based on 
cognitive impairment and intact activities of daily living 
[9], but empirical data support the presence of functional 
deﬁ   cits encompassing skills and activities beyond 
instrumental activities of daily living (ADLs), many of 
them subtle [10-15]. Functioning therefore emerges as an 
area of potential value for patient self-report. Two other 
areas with substantial prior research on patient self-
report in AD and MCI are neuropsychiatric symptoms 
and health-related quality of life.
Th   ere are of course several important obstacles to use 
of patient self-report in cognitive impairment. Disease-
related disruptions to memory and cognition may inter-
fere with the ability to complete a questionnaire accu-
rately, as might loss of insight with progressive disease 
[16], leading to reliance on informant and clinician report 
[15]. However, accuracy of informants, especially family 
caregivers, can also be suboptimal for multiple reasons, 
including the distortions introduced by caregiver depres-
sion and lack of caregiver awareness of some symptoms 
(for example, [17]).
Th  e focus of this overview is on the value of patient 
report for evaluating disease course and treatments in 
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© 2011 BioMed Central LtdMCI and in prodromal, or ‘early’ AD [18]. Th  e  emphasis 
is on early disease, corresponding to newer terminology 
referencing prodromal AD, as well as to the less speciﬁ  c 
‘mild cognitive impairment’ referenced by Petersen and 
colleagues [9].
Methods and fi  ndings
Domains important for patient report in cognition were 
identiﬁ  ed based on literature reviews completed for the 
Cognition Initiative, now the Cognition Working Group 
of the Critical Path Institute, between August 2009 and 
January 2011. Initial searches were limited to the period 
from January 2004 to June 2009 with subsequent updates 
through March 2011. Functioning, variously deﬁ  ned, 
emerged as an important area for self-report in early 
disease. Th  ere has been recent PRO measure develop-
ment and empirical studies in the areas of complex ADL 
functioning and neuropsychological aspects of func  tion-
ing (for example, executive functioning); additional work 
in self-reported neuropsychiatric symptoms and health-
related quality of life was also identiﬁ  ed. Each of these 
areas is considered brieﬂ  y below, followed by a discussion 
of the role of insight in patient self-report. Details of the 
search and literature review are available below. A 
summary of selected measures is presented in Table 1.
Search methods
Th   e initial literature search strategy targeted publications 
on AD and MCI (speciﬁ  cally ‘AD, moderate to severe’ 
and ‘MCI or very early AD’), crossing this literature with 
speciﬁ   c domain terms (functioning, functional status, 
executive functioning, HRQL, aﬀ  ect/mood/behavior). 
Th   e search was limited to English language publications 
from 2004 to 2009 in MedLine and Embase. To ensure 
that relevant measures used in clinical trials for currently 
marketed AD drugs were included, separate searches 
were conducted for MCI and AD in each domain of 
interest, limited to 1999 to 2009, with the main focus on 
‘Alzheimer’s disease’ OR ‘mild cognitive impairment’ OR 
‘cognitive impairment no dementia.’ Since treatment 
eﬃ     cacy was not the focus of this review, but rather 
measures used to assess eﬃ   cacy and eﬀ  ectiveness from 
the perspective of patients and caregivers, this part of the 
search was limited to review articles. Searches were 
conducted in PubMed initially, followed by Medline, 
Cochrane Library of Systematic Reviews, PsychINFO, 
and Embase.
Full articles were retrieved if information on measure 
development, psychometric evaluation, and/or use were 
mentioned in the abstract. Information from retrieved 
articles was abstracted into tables addressing each of 
these elements. All relevant titles and abstracts were 
screened (level 1). Full papers were obtained for any 
studies considered potentially eligible or where 
un  cer  tainty existed as to whether a paper should be 
included in the review. Full papers were formally assessed 
for relevance (level 2). Level 1 and 2 reviews for the 
literature review conformed to pre-determined inclusion 
and exclusion criteria, including focus on early AD/MCI 
patients, and caregiver- and patient-reported outcomes 
were included. Electronic data extraction forms were 
completed by reviewers trained in the critical assessment 
of evidence. A third reviewer independently examined 
any inconsistencies in extracted data elements between 
extractors and missing data ﬁ  elds. Any discrepancies in 
extracted data were resolved by consensus and any 
disagreements were resolved by consulting with a third 
investigator, as necessary. Th  e consensus version of the 
extracted data was subsequently exported to the evidence 
tables. Th  e extracted data elements from each accepted 
study included study design and measures, instruments, 
and domains and items of interest.
Patient-reported outcome measurement by 
domain
Everyday functioning: complex activities of daily living
Deﬁ   nitions of ‘functioning’ vary but generally include 
both basic activities of daily living (for example, bathing, 
dressing) and instrumental activities of daily living (for 
example, handling ﬁ  nances, cooking, phone use)     [19-21], 
with the latter set widely used to assess MCI and 
prodromal AD [22-32]. Th  e term ‘everyday functioning’ 
is used to indicate basic, instrumental, and complex or 
‘higher order’ ADLs (for example, planning social func-
tions; see, for example, [33]).
Consensus on the speciﬁ   c functional deﬁ  cits  that 
charac  terize MCI or prodromal AD has not been 
reached, especially since early deﬁ   nitions of MCI 
required the absence of functional deﬁ  cits. Th  e  presence 
of MCI, as well as subtlety of functional deﬁ  cits relative 
to AD, is now recognized [34].
Many AD functioning measures exist given the 
centrality of functioning to the expression of disease, but 
most are informant reported, including in: the Physical 
Self-Maintenance Scale [35-37]; the Blessed Dementia 
Scale [36-38]; the Dependence Scale in Alzheimer’s 
Disease [39]; the Disability Assessment for Dementia 
Scale [40,41]; the Interview for Deterioration in Daily 
Living Dementia [42,43]; and the Progressive Deteriora-
tion Scale [44].
Like most measures of functioning used in AD, the 
Alzheimer’s Disease Cooperative Study Activities of Daily 
Living (ADCS-ADL) was developed as an interview-
based informant-reported measure of level of indepen-
dence in speciﬁ  c tasks [45]. Subsequently, a version for 
use with MCI, the ADCS ADL-MCI, was developed with 
both informant- and patient-completed versions; item 
content includes complex and instru  mental ADLs, such 
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Page 5 of 12as handling ﬁ  nances, shopping, travel, and remembering 
appointments [46]. To meet the need for a brief in-home 
rated ADL measure, the Activities of Daily Living 
Prevention Instrument was developed by the Alzheimer’s 
Disease Cooperative Study Prevention Instrument 
Project, and is based in part on items from the ACDS 
ADL-MCI, the Functional Activities Questionnaire [47], 
and the Disability Assessment for Dementia Scale 
[46,48-52]. Th  ere are both patient- and informant-rated 
versions; item content overlaps substantially with the 
ADCS ADL-MCI.
Th   e ADCS Prevention Instrument Project also 
developed the Mail-In Cognitive Function Screening 
Instrument, with patient- and informant-completed 
versions. Although intended as a screening tool, item 
content includes a range of everyday functioning, includ-
ing social activities and work performance [41,42,51-54].
Th  e Patient-Reported Outcomes in Cognitive Impair-
ment (PROCOG) [14] measures the impact of MCI and 
early AD-associated cognitive impairment on multiple 
domains, including speciﬁ  c everyday functioning skills 
and social functioning. Similarly, the Perceived Deﬁ  cits 
Questionnaire addresses a range of symptoms and 
functional impacts of memory loss based on patient self-
report and has proven useful for signal detection in a 
treatment trial for MCI, although it was originally 
developed for use in multiple sclerosis [4]. Th  e  Perceived 
Deﬁ   cits Questionnaire is an example of a measure of 
‘subjective memory complaints’, most of which include 
cognition symptom report along with functioning (for 
example, Questionnaire d’auto-évaluation de la mémoire 
(QAM)/Self-Evaluation Complaint Questionnaire [55]; 
Self-Rating Scale of Memory Functions [56]).
A summary of some relevant measures is provided in 
Table 1. As noted by others, few published reports on 
functioning measures include psychometric performance 
[32], although for the measures with patient-reported 
versions, available test-retest reliability data and con-
current or predictive validity data generally indicate good 
psychometric performance, providing some evidence of 
accurate measurement. Of note is that despite content 
overlap in existing measures, some domains are relatively 
under-represented, such as social functioning or 
functioning related to language skills - both areas for 
which patient report may be particularly well-suited.
Th   e domain of functional status in cognitive disorders 
is one with a long history of scale development and use, 
and AD research is currently well-served by existing 
informant-reported scales for assessing moderate to 
severe disease. However, most item content fails to 
capture subtle deﬁ   cits, and few patient-reported 
measures have been developed to date.
Some performance-based assessments address areas 
that could be promising for adaptation as self-rated 
measures, including ﬁ   nancial capacity [57,58], facial 
emotion processing [59], and route navigation [60]. 
Linking functioning to speciﬁ  c cognitive skills through 
these and other areas may expand clinical charac-
terization of prodromal AD [61].
Because of limited use of qualitative data collection 
from patients in the measure development process, a step 
key to best practice in measure development [1], further 
reﬁ  nement of ‘functioning’ measures may be warranted, 
including through identifying and measuring aspects of 
functioning most relevant to early disease, and 
establishing consensus on the deﬁ   nition of everyday 
functioning and complex ADL functioning.
Executive functioning
Executive functioning represents the cognitive skills 
required for the planning, initiation, sequencing, and 
monitoring of complex goal-directed behavior, such as 
household chores [5,62,63]. Executive functioning impair-
ment is a criterion for dementia diagnosis [6].
Executive functioning skills underlie the everyday 
functioning skills discussed above, but are considered 
separately here because measures of executive 
functioning focus on a speciﬁ  cally deﬁ  ned set of cognitive 
skills rather than on the tasks those skills enable. Data 
from Farias and colleagues [64,65] support distinguishing 
between measurement of daily living skills and measure-
ment of neuropsychological functioning, based on data 
showing a moderate correlation between measures of 
each in a sample with AD (see also [66]). More recently, 
data from the Advanced Cognitive Training for 
Independent and Vital Elderly (ACTIVE) Cognitive 
Intervention Trial also support this distinction, as well as 
the relationship between cognitive skills and everyday 
functioning [67].
Executive functioning measures that have been used in 
MCI include the Behavior Rating Inventory of Executive 
Function - Adult version [68] (BRIEF-A [69]) and the 
Frontal Systems Behavior Scale [70,71], with patient- and 
informant-reported versions for each. Th  e BRIEF is a 
measure of everyday behavioral manifestations of 
executive control and is sensitive to subtle changes in 
MCI patients and those with cognitive complaints 
[68,72]. Similar to ﬁ  ndings from Farias and colleagues 
[65], BRIEF-A scores were only modestly correlated to 
neuropsychological measures of executive functioning, 
suggesting that self- and informant report provides 
unique information about executive functioning relative 
to performance-based measures. Th  e Frontal Systems 
Behavior Scale is a rating scale of apathy, disinhibition, 
and executive function and has demonstrated sensitivity 
to impairment in an MCI sample [70].
Measures of executive functioning show promise for 
detection of subtle deﬁ   cits in MCI [70,71]. As noted 
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structured input from patients in accordance with best 
practice for measure development may usefully expand 
the set of relevant impacts to measure and/or aid with 
identifying diﬀ  erential importance of content from the 
patient perspective and by stage of disease.
Neuropsychiatric symptoms
Although neuropsychiatric symptoms are frequently an 
important part of the disease course of AD, their 
presence earlier in the disease is not as well-established. 
In recognition of the unique presentation and possible 
prognostic signiﬁ   cance of major depressive disorder 
within AD, the National Institute of Mental Health 
developed a modiﬁ   ed provisional set of criteria for 
depression in AD, distinct from the DSM-IV (Diagnostic 
and Statistical Manual of Mental Disorders, Fourth 
Edition) criteria for major depressive disorder [73,74]. 
Work with these criteria has indicated that the prevalence 
of major depressive disorder is signiﬁ  cantly  under-
estimated in this population relative to DSM-IV-based 
prevalence estimates [74,75].
Behavioral and psychological symptoms are evident 
among some MCI and mild AD patients [11], and at 
elevated rates relative to the normal aging population 
[76]. Increased apathy and executive dysfunction have 
been documented in MCI [70,77]. Th  ere is preliminary 
evidence for higher rates of neuropsychiatric symptoms 
such as depression, anxiety, agitation, disinhibition, 
irritability, and sleep problems among those with 
executive dysfunction type MCI relative to both amnestic 
and non-amnestic MCI [76] and presence of depression 
(based on caregiver report) has been found to be 
predictive of progression from amnestic MCI to AD [75].
Few measures of neuropsychiatric symptoms have self-
report versions and few are validated for use in early 
disease. Further research is required to develop evidence 
for the validity of patient self-report for these symptoms.
Health-related quality of life
Health-related quality of life (HRQL) is the subjective 
assessment of an individual’s psychological, physical and 
social functioning or well-being [78,79] and is tradition-
ally measured via self-report, although for AD, measures 
have both patient- and informant reported versions 
[80,81]. No MCI-speciﬁ   c HRQL scale exists; instead, 
existing AD measures have been used in MCI (for 
example, the Alzheimer’s Disease Related Quality of Life 
instrument [82]) as have generic measures (deﬁ  ned as 
measures intended for use with any population or 
therapeutic area; examples are the World Health 
Organization Quality of Life questionnaire, short version 
[83] and Short-Form (SF)-12 [84]). A systematic review of 
clinical trials in AD found very low use of HRQL 
measures (in <5% for trials conducted through part of 
2006) [85]. Data from a small sample suggest that 
reliability and validity of HRQL self-report in MCI and 
AD is correlated with insight level [86]. While HRQL 
measures have been central to the rise of PRO assessment 
over the past two decades, the value of disease-speciﬁ  c 
HRQL assessment to treatment evaluation in MCI and 
prodromal AD is limited by lack of consensus on domains 
to include and lack of clarity about how to weight domains 
for scoring. Th   e HRQL impact of MCI, distinct from that 
of later disease, remains to be deﬁ   ned. Further work 
exploring the relationship of HRQL to functioning, 
neuropsychological disease eﬀ  ects, and neuropsychiatric 
symptoms would enhance the quality of HRQL measure-
ment and improve its usefulness for research applications.
Insight and patient self-report
Insight into illness is a critical issue for patient self-report 
in MCI and AD given that insight into disease eﬀ  ects 
declines as the disease progresses [87-91]. Lack of insight 
is deﬁ   ned as lack of the ability to elaborate on the 
experience of a disease, label the symptoms of the disease 
as pathological, or have knowledge of the deeper eﬀ  ects 
that the symptoms or disease will have on one’s environ-
ment [92]. Anosognosia is deﬁ   ned as unawareness of 
deﬁ  cits, speciﬁ  c cognitive dysfunction, and lack of insight 
[16,93-96]. Th  e terms ‘lack of insight’ and ‘anosognosia’ 
are used largely interchangeably in the cognitive impair-
ment literature.
Th   e relationship of insight to progression in MCI is less 
clear than it is for AD. For a review of insight in MCI see 
[95]. Th   ere is currently no consensus on the best method 
to measure insight. Most methods rely on informant 
report as a ‘gold standard’ with patient/informant concor-
dance taken as an indirect measure of patient insight. 
When the informant is the caregiver, accuracy of report 
bears critical examination. Caregiver burden, level of 
depression and anxiety, and caregiver health, including 
cognitive health, may inﬂ   uence accuracy of caregiver 
report (for example, [97,98]).
Within the AD literature, there has been examination 
of concordance along with caregiver factors in reporting 
[17,86,99,100]. Data on patient/informant concordance 
and informant accuracy are limited for the milder levels 
of cognitive impairment. In general, data support an 
inverse correlation between insight and severity of 
cognitive impairment and an inverse correlation between 
patient and caregiver report and severity of cognitive 
impairment [88,101,102]. Dementia patients likely under-
estimate their deﬁ  cits in comparison to caregiver infor-
mants [103], with concordance further reduced as disease 
progresses (for example, [104]).
Some empirical reports conclude MCI patients have 
preserved insight. For example, Farias and colleagues [15] 
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reports of others, suggesting that MCI patients do not 
under-report actual deﬁ  cits in cognition and functioning. 
Other studies suggest lack of MCI patient insight (see 
[95] for a review). Conﬂ  icting ﬁ  ndings about insight and 
ability of patients to self-report may be due to diﬀ  erent 
deﬁ  nitions of insight, diﬀ  erent deﬁ  nitions of MCI, and/or 
diﬀ  erent methods of measuring insight. Most studies of 
insight focus on insight for memory functioning; few 
studies address insight for other cognitive skills, everyday 
functional abilities, behavior, or aﬀ  ect [95]. Th  e current 
literature on insight in MCI is limited by lack of 
speciﬁ  city about domains aﬀ  ected, a critical point given 
evidence of diﬀ   erential insight by domain for MCI 
patients [91,105-107]. Insight may be well-preserved in 
some domains across a range of disease severity, but may 
diminish more rapidly in others [95]. For example, 
Clement and colleagues [91] found that some but not all 
domains assessed corresponded to performance deﬁ  cits 
in global cognitive score and executive functioning for 
MCI patients, suggesting MCI patients may be aware of 
general cognitive deﬁ   cits but not speciﬁ  c  memory 
deﬁ  cits. To date, the literature on MCI supports the con-
clusion that insight in MCI is not a single construct and 
that insight might be spared for some but impaired for 
other domains (see Roberts and colleagues [95] for a 
review).
Evidence suggests that MCI patients may have 
knowledge of deﬁ   cits in advance of when deﬁ  cits  are 
clinically discernible [108-110]. Kalbe and colleagues [93] 
found that MCI patients overestimate cognitive deﬁ  cits 
relative to informants on a 13-domain complaint inter-
view; mild AD patients underestimate their deﬁ  cits 
relative to an informant. Th   e validity of the conclusion of 
‘overestimation’ is worth challenging, however, as early 
cognitive loss may be apparent to the patient but no one 
else, in part because of the nature of the deﬁ  cits and in 
part because MCI patients may actively hide symptoms 
from others.
To optimize patient self-report, further research is 
warranted to determine the relationship of insight to 
level of disease severity, attending to potential diﬀ  erences 
in insight by domain rather than treating insight as a 
single global construct. It will be particularly interesting 
to identify those domains for which patients, especially 
MCI patients, may have the most accurate view of 
performance relative to other informants, including 
clinicians.
Some patient-reported insight scales are presented in 
Table 1.
Conclusion
Th   e increasing interest in MCI due to AD [2], preclinical 
AD [111], and prodromal AD [18] presents an 
oppor  tunity to advance outcomes measurement in 
cognitive disorders by addressing ceiling eﬀ  ects  of 
existing measures and by expanding the range of 
measurement targets beyond neuropsychological 
assessments into the realm of patient-reported outcomes. 
Patient self-report also oﬀ  ers a means of expressing, and 
perhaps quanti  fying, the clinical signiﬁ  cance of speciﬁ  c 
clinical changes.
Progress in identiﬁ  cation of treatments for cognitive 
impairment depends on accurate measurement. Among 
the concepts for which patient self-report could be 
valuable, and for which measurement appears feasible 
based on available psychometric data, are aspects of 
everyday functioning and complex activities of daily 
living and some aspects of executive functioning. Few 
measures currently address these concepts. Further, 
domains included in existing measures vary and no 
measure is comprehensive; consensus on speciﬁ  c func-
tioning domains relevant to early disease would improve 
measurement. Th   e extent to which under-studied areas, 
such as social functioning and language skills, are useful 
to assess is uncertain given lack of data.
Subtle changes in mood and aﬀ  ect speciﬁ  c to MCI may 
be usefully captured by self-report but to date there are 
limited data on validity of patient self-report of neuro-
psychiatric symptoms in early disease. Measurement of 
the health-related quality of life impact of MCI has 
proceeded largely on the basis of measures developed for 
AD; relevance to the MCI experience remains to be 
established. Understanding the MCI experience in 
greater depth can improve conceptualization of HRQL. 
Currently, HRQL assessments in MCI and mild AD are 
based largely on existing AD measures with little psycho-
metric performance data on suitability for measurement 
of milder levels of impairment.
Other domains may prove useful to explore for self-
report. For example, cognitive impairment is often 
associated with somatic changes, including changes in 
eating behavior, such as dysphagia, along with weight 
loss, changes in olfaction, sleep quality, balance, and 
increased fall risk [112-119].
Th  e impact of ﬂ  uctuating or declining insight in mild 
cognitive impairment on patient report is unclear. At 
what point does loss of insight make patient self-report 
no longer reliable and valid? Current research suggests 
that this point may vary by domain, with patients 
demonstrating suﬃ     cient insight to reliably and validly 
self-report about disease-related impairment in some 
areas well into mild to moderate AD.
Consideration of strategies for quantifying the impact 
of other variables on the accuracy of measurement 
should be part of measure validation. Cultural diﬀ  erences 
in symptom expression and interpretation are one 
example. Item response theory methods will likely be of 
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quantifying cultural confounds [120-122]. In addition to 
the possibilities of new measure development, such as is 
being undertaken by the Cognition Working Group of 
the Critical Path Institute’s PRO Consortium, existing 
AD measures could be tested in the MCI population and 
converted to self-report if feasible.
Th  e increasing emphasis of research on symptoms, 
correlates, and impact of cognitive impairment at mild 
levels suggests that the time is right for development of 
new patient-reported measures for MCI. Although 
measure  ment from the perspective of patients with MCI 
and prodromal AD is still at an early stage, the develop-
ment of new measures and psychometric evaluation of 
existing AD measures for use in early disease should be 
pursued to increase the tools available and to expand our 
understanding of mild levels of cognitive impairment.
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